Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616962 · ClinicalTrials.gov registry record · NA
Vasculera in Participants With Lipedema
A NA study of Lipedema, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05616962: Completed NA study of Lipedema, sponsored by Primus Pharmaceuticals.
NCT05616962 is a NA study of Lipedema that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 34 participants, below the 209-participant average among 4 other Lipedema trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05616962, a NA study of Lipedema, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to gain preliminary information via a uniform protocol regarding the clinical effects of Vasculera in participants with lipedema and the possible role of the glycocalyx as a physiological target for Vasculera activity. It is anticipated that the results of this case study will inform the development of a formal randomized, double-blind, placebo controlled trial.
Primary Outcome
Weight in kilograms on digital, calibrated bathroom scale
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Diosmiplex
Study Locations (1)
Arizona
- Primus Pharmaceuticals - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-26 |
| Est. Completion | 2019-09-23 |
| Phase | NA |
What the finished NCT05616962 record still lists
NCT05616962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 209-participant average among 4 other Lipedema trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Lipedema appearing as the primary indexed condition, and to 1 intervention - of which Diosmiplex is the first listed.
NCT05616962 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05616962 about?
NCT05616962 is a clinical study titled "Vasculera in Participants With Lipedema". This study is designed to gain preliminary information via a uniform protocol regarding the clinical effects of Vasculera in participants with lipedema and the possible role of the glycocalyx as a physiological target for Vasculera activity. It is anticipated that the results of this case study will...
What is the current status of trial NCT05616962?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2019-05-26. Estimated completion is 2019-09-23.
What conditions does trial NCT05616962 study?
This clinical trial studies the following conditions: Lipedema.
What interventions are being tested in trial NCT05616962?
The interventions under investigation include: Diosmiplex (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05616962?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05616962 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI